This product is antibody recognizes Cytokeratin K8/K18. The antibody COU-1 can be used in some immunoassay techniques such as: WB.
Figure 1 Binding of COU-1 to recombinant K8/K18 complexes evaluated by ELISA.
Heterotypic complexes, generated by combining purified recombinant K8-(1–129) or intact K8 with purified recombinant K18-(1–124) or intact K18 in equimolar ratios, were coated at 5 g/ml on ELISA plates and incubated with serial dilutions of COU-1.
Ditzel, H. J., Strik, M. C., Larsen, M. K., Willis, A. C., Waseem, A., Kejling, K., & Jensenius, J. C. (2002). Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. Journal of Biological Chemistry, 277(24), 21712-21722.
Figure 2 Purification of cytokeratin from colon cancer tissue.
Western blot-stained with COU-1.
Ditzel, H. J., Strik, M. C., Larsen, M. K., Willis, A. C., Waseem, A., Kejling, K., & Jensenius, J. C. (2002). Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. Journal of Biological Chemistry, 277(24), 21712-21722.
Figure 3 Subcellular distribution of N-terminally truncated K8/K18 recognized by COU-1 and intact K18 recognized by a murineanti-K18 antibody.
Bound COU-1 wasdetected with FITC-goat anti-human-chain antibody (green) and bound anti-K18 with Texas Red goat anti-mouse IgG antibody (red).
Ditzel, H. J., Strik, M. C., Larsen, M. K., Willis, A. C., Waseem, A., Kejling, K., & Jensenius, J. C. (2002). Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. Journal of Biological Chemistry, 277(24), 21712-21722.
Figure 4 Subcellular distribution of N-terminal-truncated K8/K18 recognized by COU-1 and K18 recognized by a murine anti-K18antibody in MCF7 breast cancer cells.
Differential interference contrast images were included to visualize the composition of the cells. Whereas whole intermediate filamentswere stained with anti-K18 (arrowheads), COU-1 (arrows) only stained short fibrils and globular structures.
Ditzel, H. J., Strik, M. C., Larsen, M. K., Willis, A. C., Waseem, A., Kejling, K., & Jensenius, J. C. (2002). Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. Journal of Biological Chemistry, 277(24), 21712-21722.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0047LY-S(P) | Human Anti-Cytokeratin K8/K18 Recombinant Antibody (clone COU-1); scFv Fragment | WB | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0047LY-F(E) | Human Anti-Cytokeratin K8/K18 Recombinant Antibody (clone COU-1); Fab Fragment | WB | Human Fab |
There are currently no Customer reviews or questions for HPAB-0047LY. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.